EUROPEAN  MEDICINES  AGENCY  VALIDATES  MARKETING  APPLICATION  FOR  FILGOTINIB  FOR  THE  TREATMENT  OF  ULCERATIVE  COLITIS

-- Application Based on Results from Pivotal Phase 2b/3 SELECTION Trial --

Foster City, Calif., & Mechelen, Belgium, November 2, 2020, 22.01 CET – Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the application for a new indication to the approved license for filgotinib 200 mg, an oral JAK1 preferential inhibitor, has been validated and is now under evaluation by the European Medicines Agency (EMA). The proposed indication is for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. 

Click to view original post